| |
Quarterly Update - June 30, 2010
Overview
Neuraxon Inc., is designing and developing next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS). The company announced in January, that it has been awarded a grant of $267,000 from the Michael J. Fox Foundation for Parkinson's Research (MJFF). Under the grant, Neuraxon will seek to develop custom-designed, small-molecule, selective nNOS inhibitors. These compounds will be tested for the potential to reduce brain and systemic nitric oxide levels as well as the potential to demonstrate improved neuroprotective properties in in vitro and in vivo preclinical models of Parkinson's disease.
Fund Performance*
As at June 30, 2010
|
Fund |
1 Year |
3 Years |
5 Years |
Since Inception |
| Series I |
-17.60% |
-14.93% |
-13.30% |
-8.81% |
| Series II |
-20.04% |
-16.41% |
-14.75%
|
-12.01% |
| Series III |
-19.15% |
-15.57% |
-14.01%
|
-11.36% |
*Source: Globefund.com
Feature Investee Profile
Insception Biosciences
|
|
Total Investment: $9.5 million
Initial Investment Date: December 2001
Location: Mississauga, Ontario
Sector: Health Services
Investment Structure: Equity
Investor Status: Board Seat
Web: www.insception.com |
Insception Biosciences has established itself as a leader in the field of umbilical cord blood cellular therapies. The company operates the largest and most established cord blood program in Canada at its state-of-the-art facility located in Mississauga, Ontario, Canada. Insception's research and development division is developing a pipeline of cellular therapy products to improve on and extend the medical uses of cord blood. These include products for blood (bone marrow) applications and for non-boold applications such as peripheral vascular disease, neurological disorders and diabetes.
| |
|
